DZ2376A1
(fr)
*
|
1996-12-19 |
2002-12-28 |
Smithkline Beecham Plc |
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
|
PL338016A1
(en)
|
1997-07-11 |
2000-09-25 |
Smithkline Beecham Plc |
Novel chemical compounds
|
WO1999038845A1
(en)
|
1998-01-29 |
1999-08-05 |
Tularik Inc. |
Ppar-gamma modulators
|
GB9803411D0
(en)
*
|
1998-02-18 |
1998-04-15 |
Smithkline Beecham Plc |
Novel compounds
|
US6194410B1
(en)
|
1998-03-11 |
2001-02-27 |
Hoffman-La Roche Inc. |
Pyrazolopyrimidine and pyrazolines and process for preparation thereof
|
GB9810671D0
(en)
*
|
1998-05-18 |
1998-07-15 |
Pfizer Ltd |
Anti-pruritic agents
|
GB9818916D0
(en)
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
GB9818914D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
GB9820113D0
(en)
|
1998-09-15 |
1998-11-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
GB9926302D0
(en)
*
|
1999-11-05 |
2000-01-12 |
Smithkline Beecham Plc |
Novel compounds
|
WO2001045694A1
(en)
*
|
1999-12-21 |
2001-06-28 |
Smithkline Beecham Corporation |
Urotensin-ii receptor antagonists
|
SE9904723D0
(sv)
*
|
1999-12-22 |
1999-12-22 |
Carlsson A Research Ab |
New modulators of dopamine neurotransmission II
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
SE0002754D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New pharmaceutical combination formulation and method of treatment with the combination
|
US6818639B2
(en)
|
2000-07-21 |
2004-11-16 |
Biovitrum Ab |
Pharmaceutical combination formulation and method of treatment with the combination
|
US6399617B1
(en)
|
2000-07-21 |
2002-06-04 |
Biovitrum Ab |
Use
|
SE0002739D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New use
|
WO2002022595A1
(fr)
*
|
2000-09-18 |
2002-03-21 |
Toa Eiyo Ltd. |
Derives de benzothiophenesulfonamide substitue en n
|
US7071220B2
(en)
|
2000-09-18 |
2006-07-04 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
US7034029B2
(en)
|
2000-11-02 |
2006-04-25 |
Wyeth |
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
|
EP1341783A1
(en)
|
2000-11-21 |
2003-09-10 |
Smithkline Beecham Plc |
Isoquinoline derivatives useful in the treatment of cns disorders
|
CN1289072C
(zh)
|
2000-12-22 |
2006-12-13 |
石原产业株式会社 |
苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
|
AU2002256418A1
(en)
*
|
2001-04-27 |
2002-11-11 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of bace
|
AR033879A1
(es)
*
|
2001-05-07 |
2004-01-07 |
Smithkline Beecham Corp |
Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
|
WO2002089785A1
(en)
*
|
2001-05-07 |
2002-11-14 |
Smithkline Beecham Corporation |
Sulfonamides
|
US20040198979A1
(en)
*
|
2001-05-07 |
2004-10-07 |
Dashyant Dhanak |
Sulfonamides
|
US6743796B2
(en)
|
2001-05-07 |
2004-06-01 |
Wyeth |
Piperazinyl-isatins
|
JP2004529168A
(ja)
*
|
2001-05-07 |
2004-09-24 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
AU2002256497A1
(en)
*
|
2001-05-07 |
2002-11-18 |
Smithkline Beecham Corporation |
Sulfonamides
|
GB0111186D0
(en)
*
|
2001-05-08 |
2001-06-27 |
Smithkline Beecham Plc |
Novel compounds
|
US7718650B2
(en)
|
2001-05-11 |
2010-05-18 |
Biovitrum Ab |
Aryl sulfonamide compounds for treating obesity
|
RS88803A
(en)
*
|
2001-05-11 |
2007-02-05 |
Biovitrum Ab., |
Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders
|
NZ528450A
(en)
|
2001-05-11 |
2006-02-24 |
Biovitrum Ab |
Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders
|
NZ529631A
(en)
|
2001-06-07 |
2006-08-31 |
F |
Indole derivatives with 5-hydroxytryptamine (5-HT) 5-HT6 receptor affinity in the treatment of disorders of the CNS
|
WO2002100822A1
(en)
*
|
2001-06-11 |
2002-12-19 |
Biovitrum Ab |
Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
|
CA2450245A1
(en)
|
2001-06-15 |
2002-12-27 |
F. Hoffmann-La Roche Ag |
4-piperazinylindole derivatives with 5-ht6 receptor affinity
|
US6727264B1
(en)
*
|
2001-07-05 |
2004-04-27 |
Synaptic Pharmaceutical Corporation |
Substituted anilinic piperidines as MCH selective antagonists
|
EP1414442A1
(en)
*
|
2001-08-07 |
2004-05-06 |
Smithkline Beecham Plc |
3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
|
HUP0401235A2
(hu)
|
2001-08-10 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
|
WO2003022272A1
(fr)
*
|
2001-09-05 |
2003-03-20 |
Eisai C0. Ltd. |
Agents stimulant l'appetit et remedes contre l'anorexie
|
SE0103644D0
(sv)
*
|
2001-11-01 |
2001-11-01 |
Astrazeneca Ab |
Therapeutic isoquinoline compounds
|
ATE429916T1
(de)
*
|
2001-11-09 |
2009-05-15 |
Biovitrum Ab Publ |
Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
|
EA200400708A1
(ru)
|
2001-11-22 |
2004-10-28 |
Биовитрум Аб |
Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
|
RS44304A
(en)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
WO2003045393A1
(en)
*
|
2001-11-30 |
2003-06-05 |
F. Hoffmann-La Roche Ag |
Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
|
US20070270432A1
(en)
*
|
2002-02-05 |
2007-11-22 |
James Hagan |
Novel Method
|
EP1474401A2
(en)
*
|
2002-02-05 |
2004-11-10 |
Novo Nordisk A/S |
Novel aryl- and heteroarylpiperazines
|
US20050222124A1
(en)
*
|
2002-02-13 |
2005-10-06 |
Bromidge Steven M |
Benzenesulfonamide derivatives as antipsychotic agents
|
JP2005517705A
(ja)
*
|
2002-02-13 |
2005-06-16 |
グラクソ グループ リミテッド |
ベンゼンスルホンアミド誘導体ならびにドーパミンd3およびd2受容体リガンドとしてのその使用
|
JP2005522452A
(ja)
*
|
2002-02-13 |
2005-07-28 |
グラクソ グループ リミテッド |
Cns疾患の治療のための、5−ht6受容体アフィニティーを有する7−アリールスルホンアミド−2,3,4,5−テトラヒドロ−1h−ベンゾ’ジアゼピン誘導体
|
PL209872B1
(pl)
|
2002-03-27 |
2011-10-31 |
Glaxo Group Ltd |
Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
|
US20040142948A1
(en)
*
|
2002-05-07 |
2004-07-22 |
Dashyant Dhanak |
Sulfonamides
|
PL211057B1
(pl)
*
|
2002-05-13 |
2012-04-30 |
Hoffmann La Roche |
Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny
|
AU2003243091A1
(en)
*
|
2002-06-20 |
2004-01-06 |
Biovitrum Ab (Publ) |
New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
|
JP4754821B2
(ja)
*
|
2002-06-20 |
2011-08-24 |
プロキシマゲン・リミテッド |
肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物
|
EP1897881A3
(en)
|
2002-06-20 |
2009-03-18 |
Biovitrum AB (publ) |
Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
|
BR0315317A
(pt)
|
2002-10-18 |
2005-09-06 |
Hoffmann La Roche |
4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6
|
WO2004043368A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Smithkline Beecham Corporation |
Sulfonamides
|
AU2003291262A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
PL377847A1
(pl)
|
2003-01-14 |
2006-02-20 |
Arena Pharmaceuticals Inc. |
1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
|
US7153858B2
(en)
|
2003-01-31 |
2006-12-26 |
Epix Delaware, Inc. |
Arylpiperazinyl compounds
|
EP1597322A2
(de)
*
|
2003-02-13 |
2005-11-23 |
LANXESS Deutschland GmbH |
Metallkomplexe als lichtabsorbierende verbindungen in der informationsschicht von optischen datenträgern
|
CA2767153A1
(en)
*
|
2003-02-20 |
2004-09-02 |
Encysive Pharmaceuticals Inc. |
Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
|
TWI289141B
(en)
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
US7262197B2
(en)
*
|
2003-03-31 |
2007-08-28 |
Janssen Pharmaceutica, N.V |
Phospholipase C inhibitors for use in treating inflammatory disorders
|
US6946466B2
(en)
*
|
2003-04-10 |
2005-09-20 |
Schering Ag |
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
|
US20040204422A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Abbott Gmbh & Co. Kg. |
N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
|
RS20060035A
(en)
|
2003-07-22 |
2008-08-07 |
Arena Pharmaceuticals Inc., |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
GB0320320D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Glaxo Group Ltd |
Novel compounds
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
AU2004299438A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Biovitrum Ab |
Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
|
SE0303480D0
(sv)
|
2003-12-19 |
2003-12-19 |
Biovitrum Ab |
Benzofuranes
|
RU2007107349A
(ru)
*
|
2004-07-28 |
2008-09-10 |
Глэксо Груп Лимитед (GB) |
Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
|
ES2359725T3
(es)
|
2004-09-30 |
2011-05-26 |
F. Hoffmann-La Roche Ag |
Composiciones y métodos para el tratamiento de trastornos cognitivos.
|
US7834048B2
(en)
|
2004-10-14 |
2010-11-16 |
Abbott Gmbh & Co. Kg |
Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
|
JP4904277B2
(ja)
|
2004-10-14 |
2012-03-28 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
ドーパミンd3受容体の調節に応答する障害の治療に好適な複素環化合物
|
WO2006062481A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Biovitrum Ab |
New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
|
EP1676841A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Esteve Laboratorios Dr. Esteve S.A. |
Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
|
WO2006075808A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Inje University |
Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease
|
RU2499795C2
(ru)
|
2005-07-04 |
2013-11-27 |
Хай Пойнт Фармасьютикалс, ЛЛС |
Антагонисты гистаминовых н3-рецепторов
|
JP5091138B2
(ja)
|
2005-08-12 |
2012-12-05 |
スヴェン・ライフ・サイエンシズ・リミテッド |
機能性5−ht6リガンドとしてのアミノアリールスルホンアミド誘導体
|
KR101250820B1
(ko)
|
2005-08-16 |
2013-04-04 |
수벤 라이프 사이언시스 리미티드 |
개선된 로사르탄 제조 방법
|
EP1976495A2
(en)
*
|
2006-01-06 |
2008-10-08 |
Aarhus Universitet |
Compounds acting on the serotonin transporter
|
AR060213A1
(es)
|
2006-03-31 |
2008-06-04 |
Glaxo Group Ltd |
Compuesto de piperazinil - piridinil -bencensulfonamida , su uso para fabricar un medicamento proceso para la preparacion del mismo composicion farmaceutica que lo comprende y proceso para prepararla
|
CN101421264A
(zh)
|
2006-04-19 |
2009-04-29 |
艾博特股份有限两合公司 |
适用于治疗对血清素5ht6受体调节有反应的病症的杂环化合物
|
UY30295A1
(es)
|
2006-04-19 |
2007-11-30 |
Abbott Gmbh & Amp |
Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
|
JP2009537596A
(ja)
|
2006-05-23 |
2009-10-29 |
ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー |
6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用
|
WO2007137968A1
(en)
|
2006-05-29 |
2007-12-06 |
High Point Pharmaceuticals, Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
CA2669117A1
(en)
*
|
2006-10-26 |
2008-05-02 |
Gary A. Flynn |
Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
|
DK2114878T3
(da)
|
2007-01-08 |
2011-03-14 |
Suven Life Sciences Ltd |
5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander
|
KR101132577B1
(ko)
|
2007-01-10 |
2012-04-05 |
에프. 호프만-라 로슈 아게 |
키마아제 억제제로서의 술폰아미드 유도체
|
KR20090123977A
(ko)
|
2007-03-23 |
2009-12-02 |
애보트 게엠베하 운트 콤파니 카게 |
세로토닌 5-ht6 수용체의 조절에 반응하는 장애를 치료하는데 적합한 아제티딘 화합물
|
SI2155674T1
(sl)
|
2007-05-03 |
2011-10-28 |
Suven Life Sciences Ltd |
Aminoalkoksi aril sulfonamid spojine in njih uporaba kot 5-ht6 ligandi
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
EP2016943B1
(en)
*
|
2007-07-19 |
2011-02-23 |
Laboratorios del Dr. Esteve S.A. |
Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
|
CA2703157C
(en)
|
2007-10-26 |
2013-02-05 |
Suven Life Sciences Limited |
Amino arylsulfonamide compounds and their use as 5-ht6 ligands
|
CL2008003232A1
(es)
*
|
2007-11-02 |
2009-11-27 |
Abbott Gmbh & Co Kg |
Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
|
WO2009074607A1
(en)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
JP2011524365A
(ja)
*
|
2008-06-11 |
2011-09-01 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
マラリアの処置に有用な化合物および組成物
|
EA019496B1
(ru)
|
2008-09-17 |
2014-04-30 |
Сувен Лайф Сайенсиз Лимитед |
Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
|
US8318725B2
(en)
|
2008-09-17 |
2012-11-27 |
Suven Life Sciences Limited |
Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
UA100192C2
(en)
|
2008-11-11 |
2012-11-26 |
УАЙТ ЭлЭлСи |
1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
|
KR101073703B1
(ko)
|
2009-04-07 |
2011-10-14 |
한국화학연구원 |
피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
|
US8362010B2
(en)
|
2009-04-30 |
2013-01-29 |
Abbott Gmbh & Co. Kg |
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
JP2012525355A
(ja)
|
2009-04-30 |
2012-10-22 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
セロトニン5−ht6受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物
|
WO2010125134A1
(en)
|
2009-04-30 |
2010-11-04 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
US8343959B2
(en)
|
2009-04-30 |
2013-01-01 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
CN102869647B
(zh)
|
2010-01-05 |
2015-06-24 |
苏文生命科学有限公司 |
作为5-ht6受体配体的砜化合物
|
BR112013008100A2
(pt)
|
2010-09-22 |
2016-08-09 |
Arena Pharm Inc |
"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
|
WO2012059431A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
WO2012059432A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
|
ES2413911B1
(es)
*
|
2011-12-15 |
2014-05-14 |
Universidad De Zaragoza |
Agente inhibidor de la agregación del peptido beta amiloide.
|
JP2015512383A
(ja)
|
2012-03-20 |
2015-04-27 |
アダムド エスピー.ゼット オー.オー.Adamed Sp.Z O.O. |
Cns疾患の処置のためのベンジルアミンのスルホンアミド誘導体
|
DK2970205T3
(da)
|
2013-03-14 |
2019-07-29 |
Tolero Pharmaceuticals Inc |
JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
|
EP3027613B1
(en)
|
2013-07-25 |
2018-03-28 |
Uniwersytet Jagiellonski |
Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
|
CN105085436B
(zh)
|
2014-04-19 |
2019-08-16 |
广东东阳光药业有限公司 |
磺酰胺类衍生物及其在药物上的应用
|
CN105367473B
(zh)
*
|
2014-08-12 |
2020-02-11 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
CN105367472B
(zh)
*
|
2014-08-12 |
2020-04-21 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
CN109562085A
(zh)
|
2015-06-12 |
2019-04-02 |
阿速万科学有限责任公司 |
用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
|
SI3310760T1
(sl)
|
2015-06-22 |
2023-02-28 |
Arena Pharmaceuticals, Inc. |
Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
|
AU2016291673A1
(en)
|
2015-07-15 |
2018-01-25 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
CN108926565A
(zh)
*
|
2017-05-26 |
2018-12-04 |
中国科学院上海生命科学研究院 |
五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
|
WO2019180176A1
(en)
|
2018-03-21 |
2019-09-26 |
Spherium Biomed, S.L. |
Composition for the treatment of schizophrenia and/or psychosis
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|